Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kalaris Therapeutics ( (KLRS) ) has issued an announcement.
On April 3, 2025, Kalaris Therapeutics, Inc. announced the election of Leone Patterson to its Board of Directors as a Class III director, with her term set to expire at the 2026 annual meeting of stockholders. Ms. Patterson was also appointed as Chair of the Audit Committee, joining Anthony Adamis, M.D., and Morana Jovan-Embiricos, Ph.D. The company plans to implement a new Non-Employee Director Compensation Program, under which Ms. Patterson will receive compensation for her board and committee service. Additionally, she will enter into an indemnification agreement with the company, ensuring protection against certain legal expenses related to her directorial role.
More about Kalaris Therapeutics
YTD Price Performance: -23.40%
Average Trading Volume: 25,503
Technical Sentiment Signal: Strong Buy
Current Market Cap: $123.9M
For an in-depth examination of KLRS stock, go to TipRanks’ Stock Analysis page.